Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge(University of Colorado Denver), Alice T. Shaw(Dana-Farber Cancer Institute), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus), Yiyun Tang(Southwest University), Jeffrey A. Engelman(Cancer Research Center), Daniel B. Costa(Beth Israel Deaconess Medical Center), Geoffrey I. Shapiro(Brigham and Women's Hospital), Benjamin Solomon(Peter MacCallum Cancer Centre), Pasi A. Jänne(Harvard University), Yung‐Jue Bang(Seoul National University), Katherine Ruffner(Pfizer (United States)), A. John Iafrate(Massachusetts General Hospital), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Keith D. Wilner(Pfizer (United States)), Patricia LoRusso(Yale Cancer Center), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Jeffrey W. Clark(Massachusetts General Hospital), Stephen B. Fox(Peter MacCallum Cancer Centre), Dong‐Wan Kim(Seoul National University Hospital), Patricia Stephenson(Rho (United States)), Eunice L. Kwak(Harvard University), Ravi Salgia(City Of Hope National Medical Center), P. Fidias(Asklepios Fachkliniken München-Gauting), Leena Gandhi(Celldex Therapeutics (United States))
Cited by 1,284
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k